SCHEMBL665488

SCHEMBL665488

c1cn2cnnc2cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30327406 0.98 CYP3A4 (0.31)
SCHEMBL3321879 0.82
SCHEMBL23832439 0.75 DRD1 (0.37)
SCHEMBL88351 0.69
Water SCHEMBL29989019 0.67 DYRK1A (0.39)
SCHEMBL8139635 0.65 PDE10A (0.33)
SCHEMBL18879058 0.63 BRAF (0.35)
SCHEMBL21644167 0.62 GSK3B (0.47)
SCHEMBL21917175 0.62 PDE2A (0.35)
SCHEMBL18879057 0.62 RET (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545682-B2 Heterocyclic derivatives as P2X7 receptor antagonists BREYE THERAPEUTICS APS (DK) 2026-02-10 US claimed
EP-4262975-B1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2025-03-05 EP claimed
US-20250034146-A1 ELECTRO-PHOTOCHEMICAL SYNTHESIS OF 1,2,4-TRIAZOLO-[4,3-A]PYRAZINE PURDUE RESEARCH FOUNDATION (US) 2025-01-30 US claimed
US-20240034737-A1 Heterocyclic Derivatives as P2X7 Receptor Antagonists BREYE THERAPEUTICS APS (DK) 2024-02-01 US claimed
EP-4262975-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Breye Therapeutics ApS (DK) 2023-10-25 EP claimed
CN-116600803-A Macrocyclic urea orexin receptor agonists 默沙东有限责任公司 2023-08-15 CN claimed
WO-2022129365-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AXXAM S.P.A. (IT) 2022-06-23 WO claimed
EP-4015039-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AXXAM S.p.A. (IT) 2022-06-22 EP claimed
EP-3125920-A2 USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER Del Mar Pharmaceuticals (CA) 2017-02-08 EP claimed
WO-2015154064-A2 USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER DEL MAR PHARMACEUTICALS (CA) 2015-10-08 WO claimed
EP-0745154-B1 MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM LIGNOZYM GMBH (DE) 1998-09-16 EP claimed
EP-0845026-A1 MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES CALL, Hans-Peter Dr. (DE) 1998-06-03 EP claimed
WO-1997048786-A1 MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES CALL HANS PETER (DE) 1997-12-24 WO claimed
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
US-5095018-A Anticonvulsants BURROUGHS WELLCOME CO. (US) 1992-03-10 US disclosed
US-5091425-A Inhibitors of the catalytic action of renin IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-25 US disclosed
EP-0402096-A3 ANTICONVULSANT PYRAZINES THE WELLCOME FOUNDATION LIMITED (GB) 1991-09-18 EP disclosed
EP-0402096-A2 Anticonvulsant pyrazines THE WELLCOME FOUNDATION LIMITED (GB) 1990-12-12 EP disclosed